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Abstract
Background: Tinospora sagittata (Oliv.) Gagnep. var. craveniana (S.Y.Hu) Lo (TSG) is a traditional Chinese herb that
has been used for the treatment of upper respiratory tract infection and has anti-bacterial and anti-ulcer activity.
Our study investigated the bactericidal effects of TSG and its major component, palmatine, against a Helicobacter
pylori (H. pylori) strain isolated from pig and the standard strain H. pylori SS1 in vitro and in vivo.
Methods: H. pylori was isolated from pig and named H. pylori SCYA201401. For in vitro experiments, the inhibitory
activity of TSG and palmatine against H. pylori SCYA201401 and H. pylori SS1 were tested by use of the agar cup
diffusion technique. The minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) were
determined from the absence of H. pylori colonies on agar plates. Time-kill curves were used to evaluate
bactericidal activity; the average number of colonies was calculated at 0 to 48 h after liquid incubation, with
concentrations of drugs at 0.5, 1, and 2 × MIC. For in vivo experiments, H. pylori SCYA201401-infected mice were
randomly divided into TSG, palmatine, triple therapy (omeprazole, clarithromycin, and amoxicillin), blank control,
and model groups. The eradication ratios were determined by use of rapid urease tests and bacterial culture.
Results: In vitro, the MIC and MBC of TSG against H. pylori SCYA201401 and SS1 were both 6250 μg/mL, whereas
palmatine against H. pylori SCYA201401 was 6.25 μg/mL and against H. pylori SS1 was 3.12 μg/mL. The time-kill
curves showed a dose-dependent, progressive decline in the numbers of viable bacteria up to 40 h. In vivo, the
eradication ratios in the TSG and palmatine groups of mice were 80 and 50 % compared with 70 % in the
triple-therapy group.
Conclusion: TSG and its major component, palmatine, have bactericidal activity against H. pylori in vitro and in vivo.
The possibility that TSG or palmatine can be effective in the treatment of human and animals H. pylori infection
deserves investigation.
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Background
Helicobacter pylori (H. pylori) is a gram-negative bacter-
ium, usually in a spiral-shaped form, which can be con-
verted into coccoid cells under a hostile environment. H.
pylori infection often is associated with gastrointestinal
diseases, such as chronic gastritis, peptic ulcer, gastric
carcinoma, and mucosa-associated lymphoid tissue
lymphoma [1–7].
H. pylori colonizes the stomach of more than half of
the world’s human population, but its mode of transmis-
sion remains unknown. Some reports indicate there is a
higher prevalence of antibodies against this bacterium in
veterinarians, butchers, and slaughterers than in other
people, which suggests the possibility of zoonotic trans-
mission [8–10]. Recently, investigators have isolated H.
pylori from cows, sheep, camels, miniature pigs, and
dogs’ milk. The isolated method for each animal is
slightly different [11, 12].
Current treatment and eradication of H. pylori involve
the use of triple therapy consisting of two antibiotics, in-
hibition of gastric acid secretion by histamine H2-antag-
onists or proton pump inhibitors, and mucosal
protection provided by sucralfate and bismuth. However,
the organism’s increasing antibiotic resistance and side
effects arising from these drugs are creating a general
health problem, indeed a global pandemic, which is es-
pecially severe in developing countries such as China
[13]. Thus, safe and effective non-antibiotic agents are
urgently needed. Accordingly, there is rekindled interest
in the use of natural drugs, including herbs, which may
possess anti-H. pylori activities [32] and also may have
minimal side effects, easy accessibility, and affordability,
even by the poor.
Traditional Chinese medicine has been used in Chinese
health care for more than two thousand years. Side effects
and adverse events of the traditional medicines are gener-
ally regarded as mild and infrequent [14–16]. Tinospora
sagittata (Oliv.) Gagnep. var. craveniana (S.Y.Hu) Lo
(TSG) is an important species of the genus Tinospora
(Menispermaceae), a traditional Chinese Miao-nationality
herb which only grows on the Mount Emei of Sichuan
province, and has been widely used in the treatment of
gastrointestinal diseases. TSG is listed in the Pharmacopeia
of the People’s Republic of China as a plant of origin for
Tinospora sagittata (Oliv.) Gagnep, with anti-inflammatory,
analgesic, anti-bacterial, anti-ulcer, anti-tumor, and anti-
stress activities [17–20]. The main chemical constituents of
Radix Tinosporae are diterpenoid lactone, protoberberine
alkaloids, aporphine alkaloids, and botanic steroids, among
which diterpenoid lactones and alkaloids are considered
important bioactive constituents. Palmatine is one of the
major alkaloid compounds in TSG.
This study isolated a clinical H. pylori strain from
swine by an improved method and investigated the
bactericidal activities of TSG and its major component,
palmatine, against the clinical H. pylori strain and H.
pylori SS1 in vivo and in vitro.
Methods
Plant collection and extraction
TSG plants were collected from Mount Emei (Sichuan,
China) between the months of September and October,
2014. The plants were identified and authenticated by
Professor Qiao-jia Fan of the College of Veterinary
Medicine, Sichuan Agricultural University, Chengdu,
China. A voucher specimen (TSG2014) was deposited in
the Veterinary Medicine Department of Sichuan Agricul-
tural University. We prepared an extract of TSG from
the plants according to reported methods [21]. Air-dried
TSG (500 g) was refluxed with 95 % ethanol (v/v) three
times each for 2 h. The solvent was completely removed
in vacuo to generate a semisolid residue, which yielded
14.72 % (w/w) dry starting material. Stock solutions of
the freeze-dried extracts were prepared for the initial
screening by reconstitution in 1 % dimethyl sulfoxide
(Amresco, America) to a final concentration of 1 g/mL.
Chemicals and reagents
Palmatine, amoxicillin, omeprazole, clarithromycin, and
vancomycin were purchased from Shanghai Yuanye Bio-
technology, Co., Ltd (Shanghai, China). Brucella broth,
Columbia blood agar, and Mueller-Hinton agar were
purchased from OXOID (Hampshire, UK).
Bacterial strain
H. pylori SS1 were purchased from the Chinese Center
for Disease Control, Beijing.
Sampling
One hundred seventy gastric samples were randomly se-
lected from pigs sent to the Xingrui slaughterhouse
(A29180101) in Ya’an, Sichuan Province, China, during
August 28, 2014. Gastric tissue samples of 0.5 to 1 cm
were obtained from the pyloric stomach immediately
after slaughtering. The samples were placed in 3 mL of
sterile Brucella broth with 30 % glycerol and transported
rapidly to the laboratory.
Culture and collection
The samples were homogenized in 1 mL Brucella broth
with 30 % glycerol by the use of sterile mortar grinders.
A 500 μL homogenate of each biopsy specimen was in-
oculated on selective agar plates (Columbia blood agar
supplemented with 7 % fresh defibrinated sheep blood
and 3 % vancomycin). Plates were incubated at 37 °C in
a microaerobic atmosphere (5 % O2, 10 % CO2,
85 % N2) for 3 to 7 days. Isolates were presumptively
identified as H. pylori on the basis of colony morphology
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(gray, small, and translucent), Gram staining, rapid ure-
ase test and biochemical reactions (oxidase, catalase, and
urease positive). The bacterial colonies were collected




Five hundred microliters of bacterium solution were
centrifuged, and DNA was extracted from the precipi-
tates with the OMEGA Bacterial DNA Kit D3350 ac-
cording to the manufacturer’s protocol. The DNA
extracts were eluted in a volume of 200 μL and stored in
a 20 °C freezer until PCR was performed.
PCR assays
PCR amplification of DNA from H. pylori strains was
performed by the use of species-specific primers
(Table 1). All PCRs were performed in 25 μL volume
and reaction mixtures containing 2.5 μL 10 × buffer
(Mg2+), 2.5 μL deoxynucleotide triphosphates (dNTPs)
at a final concentration of 0.25 mmol/L, 1 μL of each
primer at a final concentration of 0.4 μmol/L, 0.25 μL
DNA polymerase (Easy Taq, TransGen Biotech) at a final
concentration of 0.05 U/μL, and 5 μL DNA extracts.
PCR amplification of H. pylori was performed under
these conditions: 3 min of pre-incubation at 94 °C,
followed by 35 cycles of 20 s at 94 °C, 20 s at 60 °C, and
30 s at 72 °C. A final extension was performed for 5 min
at 72 °C.
The amplification products were analyzed by the use
of gel electrophoresis in 2 % agarose gels and visualized
with an ultraviolet light illuminator. Nucleotide se-
quences were searched by use of the BLAST tool on the
National Center for Biotechnology Information site
(http://www.ncbi.nlm.nih.gov/ BLAST).
Susceptibility test
Susceptibility of H. pylori strains to TSG and palmatine
was determined by use of the agar cup diffusion tech-
nique as described [22]. Inoculated plates (Mueller-Hinton
agar plates containing 5 % sheep blood) were incubated at
37 °C in an incubator under microaerophilic conditions for
3 to 7 days, after which the diameters of the zones of inhib-
ition (mm) were measured. One percent of dimethyl sulfox-
ide was included in each plate as a solvent (negative)
control; amoxicillin was included as positive controls.
Minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) tests
Minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) were determined by
the use of agar dilution methods according to the Clinical
and Laboratory Standards Institute as described [23, 24].
Briefly, the H. pylori strains were inoculated on Mueller-
Hinton agar plates containing 5 % sheep blood for 3 to
7 days. The bacterial colonies were collected and prepared
in Brucella broth with 10 % fetal calf serum. Inoculates
were prepared at a density adjusted to a 1.0 McFarland
turbidity (3 × 108 CFU/mL) standard. Serial dilutions (1:2)
of TSG were added to the Mueller-Hinton agar for final
concentrations from 200 mg/mL down to 0.39 mg/mL,
and palmatine and clarithromycin (as a positive control)
were added to the Mueller-Hinton agar for final concen-
trations from 200 μg/mL down to 0.39 μg/mL. The
no-drug containing agar and 1 % dimethyl sulfoxide agar
served as negative controls. Agar plates were inoculated
with H. pylori strains and cultured for 3 days. The MIC
was regarded as the lowest concentration that prevented
visible growth from a duplicate experiment, and the MBC
was the lowest concentration that completely inhibited
bacterial growth.
Bactericidal activities test
Bactericidal activities were evaluated by the use of time-
kill curves with 0.5, 1, and 2 ×MIC of drugs, and with
blank, clarithromycin, and 1 % dimethyl sulfoxide
controls. H. pylori SCYA201401 and H. pylori SS1
(0.1 mL at 1 × 108 CFU/mL) were added to 90-mm
plates with the calculated concentrations of drugs or di-
methyl sulfoxide and Brucella broth with 10 % fetal calf
serum (final volume 10 mL), and cultured with gentle
shaking at 37 °C in a microaerobic atmosphere. At 0, 4,
8, 12, 16, 20, 24, 32, 40 and 48 h, 0.1 mL of liquid was
removed, serially diluted, and plated on Columbia blood
agar plates (n = 2 per group). Colonies were counted and
averaged after 3 days of incubation [25].
Model establishment
A total 108 mice C57BL/6 mice (6–8 week old, male/fe-
male = 1:1, weight 25 ± 5 g) were purchased from the
specific pathogen-free facility at Chengdu Dossy Experi-
mental Animals Co., Ltd. (license No. SCXK, Sichuan,
2013–24). All experimental procedures involving animals
were approved by the Sichuan Agricultural University
Animal Care and Use Committee (registration No.
SCAU2015101801). In accordance with the Guidelines of
Table 1 Primer sequences used for H. pylori identification
Target Gene Oligonucleotides of PCR primer Products (bp)
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the International Committee on Laboratory Animals, the
animals were maintained in environmentally controlled
rooms at 20–25 °C with a relative humidity of 55 ± 5 %
and 12 h light/dark cycle. Food and water were available
ad libitum. Mice were provided with sawdust bedding
material and housed under these conditions for one week,
then fasted for 12 h prior to the experiments.
A group of 12 mice, selected randomly as blank
control, were inoculated with sterile liquid medium
(Brucella broth with 10 % fetal calf serum). A group of
48 mice (the SCYA201401experimental group) was inoc-
ulated intragastrically with 0.3 mL of H. pylori
SCYA201401 (1 × 108 CFU/mL) on three alternate days.
Another 48 mice (the SS1experimental group) were in-
oculated intragastrically with 0.3 mL of H. pylori SS1
(1 × 108 CFU/mL) on three alternate days. Animals were
fasted 24 h before and 2 h after each inoculation. After
24 days, 8 mice from the SS1 experimental group, 8
mice from the SCYA201401experimental group, and 2
mice from the control group were sacrificed by cervical
dislocation without anesthesia prior to the end of the
experiment, and used for assessing the by use of a rapid
urea test (RUT) and bacterial culture. Only if there was
a 100 % infection rate (all 18 mice positive in the RUT
and bacterial culture) was the experiment continued.
Group and drug administration
Mice of two experimental groups were randomly divided
into four groups: TSG, palmatine, triple therapy (omep-
razole, clarithromycin, and amoxicillin), and model
groups. Drugs dosages used in in vivo experiments were
equivalent to those that are used clinically. The TSG and
palmatine groups were treated intragastrically with
4 g/kg and 50 mg/kg daily for 1 week, respectively.
The triple therapy group was treated intragastrically
with a suspension of omeprazole (0.8 μg/kg), clarithro-
mycin (20 μg/kg), and amoxicillin (40 μg/kg) daily for
1 week [26]. The SS1 model group, the SCYA201401
model group, and blank control group were given
saline solution.
Eradication rate of H. pylori
At the last day of medication, all groups were deprived
of feed but allowed free access to water for 24 h and
then sacrificed. Stomachs were collected at the time of
sacrifice, opened along the greater curvature, and
washed with phosphate-buffered saline at 4 °C . Half of
the antral section was isolated for RUT determination at
room temperature within 24 h; the change to pink color
was regarded as positive. The other half of the antral
section and part of the gastric body were used for
bacterial culture according to the method described
above. Successful eradication of H. pylori was defined as
negative findings from both RUT and bacterial culture.
Statistical analysis
Eradication rates were compared among groups with a
Fisher’s exact test using SPSS 20.0 software (IBM Corp.,
Armonk, NY, United States). P < 0.05 was considered
statistically significant.
Results
Bacteria isolated and identified
Forty-two H. pylori strains were isolated from the 170
samples, a culture-positive rate of 24.7 %. A total of 128
biopsy samples were negative for H. pylori by cultivation.
A clinical H. pylori strain, containing the gene of cagA
and vacA, was named H. pylori SCYA201401and was
used to following studies.
Bactericidal activity in vitro
As illustrated in Table 2, the results of antimicrobial
susceptibility tests (zone of inhibition, MIC, and MBC)
showed that TSG and palmatine had good bactericidal
activity in vitro. There was no significant different in
susceptibility of H. pylori strains SCYA201401 and SS1.
The two strains had no visible bacterial colonies after
32-h incubation on the plate containing 6250 μg/mL
TSG. The H. pylori SCYA201401 had no visible bacterial
colonies after 40-h incubation with 6.25 μg/mL palma-
tine, and H. pylori SS1 had no growth with 3.12 μg/mL
palmatine. Those concentrations defined the MBCs of
Table 2 Results of in vitro bactericidal tests






H. pylori SCYA201401 H. pylori
SS1
H. pylori SCYA201401 H. pylori
SS1
H. pylori SCYA201401
No-drugs 0 0 - - - -
1 % DMSO 0 0 - - - -
TSG 15.00 ± 0.12 15.48 ± 0.08 6250 6250 6250 6250
Palmatine 22.18 ± 0.00 21.24 ± 0.02 3.12 6.25 3.12 6.25
Clarithromycin 16.12 ± 0.10 23.20 ± 0.12 32 16 32 16
Notes: TSG, Tinospora sagittata (Oliv.) Gagnep. var. craveniana (S.Y.Hu) Lo (TSG), DMSO dimethyl sulfoxide
Rong et al. BMC Complementary and Alternative Medicine  (2016) 16:331 Page 4 of 8
these agents. The results of the antimicrobial susceptibil-
ity tests revealed also that the bactericidal activity of
palmatine against the H. pylori in vitro was significantly
more than that of clarithromycin.
Figures 1 and 2 show the time-kill curves of H. pylori
SCYA201401 exposed to TSG or palmatine. The average
colony count of the blank control and dimethyl sulfoxide
control groups increased progressively at every time
point. In contrast, the colony counts of the TSG and
palmatine groups decreased steadily and did so in a
dose-dependent manner. Clarithromyin similarly killed
H. pylori SCYA201401.
Bactericidal activity in vivo
The establishment of the H. pylori-infected mice model
was evaluated in two ways: identification of H. pylori
isolated from gastric tissues and the RUT. The bacteria
were identified via Gram staining, RUT, and oxidase test
and catalase tests. These experiments documented that a
H. pylori-infected model was successfully established.
H. pylori eradication rates in the mouse model, deter-
mined with RUT and bacterial culture, are presented in
Table 3. TSG was as effective as triple therapy, but
palmatine was modestly less effective than those two
treatments.
Discussion
The major goal of this study was to determine the
bactericidal activities of TSG and its major component,
palmatine, against H. pylori. The rationale underlying
the goal is that the current antibiotic treatments of H.
pylori are becoming less effective and have unwanted
side effects and consequences, so effective and safer
treatments, perhaps herbal medications, have been
needed. In order to accomplish the study’s goal we
invoked a strategy of isolating H. pylori from pigs,
inoculating mice with the H. pylori, and testing the
effectiveness of the traditional Chinese medication, TSG,
and its principal active component, palmatine, against
the isolated H. pylori and standard strain H. pylori SS1
in vitro and in vivo. The principal findings of the study
are that H. pylori isolated from pig could readily
colonize mouse stomach and that treatment of H. pylori-
infected mice with TSG completely eliminated the H.
pylori. Thus, the results support the notion that a trad-
itional Chinese medication, TSG, may have therapeutic
potential against human H. pylori infection.
TSG belongs to Tinosporae (Menispermaceae), which
consists of about 34 species, with 8 species found in
China. Recent studies have shown that the ethanol
extract of Radix Tinosporae significantly inhibited
xylene-induced ear edema and acetic acid-induced
writhing in mice [20]. TSG has been used in treatment
of gastritis and peptic ulcers by the Hmong for more
than a thousand years. The chemical constituents of
Radix Tinosporae mainly include diterpenoid lactone,
protoberberine alkaloids, aporphine alkaloids, and botanic
steroids, among which diterpenoid lactones (columbin)
and alkaloids (columbamine, jatrorrhizine, palmatine) are
considered important bioactive constituents. Phytochem-
ical studies have shown that columbamine, jatrorrhizine,
palmatine and menisperine are major diterpenoid lactones
and alkaloids compounds in Radix Tinosporae [33].
Although no investigations on antibacterial activity of
TSG, columbamine, jatrorrhizine and menisperine against
H. pylori have been reported, there are a few reports on
palmatine; 16 μg/mL palmatine in vitro or 50 mg/kg in
vivo killed H. pylori [34, 35].
Fig. 1 Time-kill curves of Tinospora sagittata (Oliv.) Gagnep. var. craveniana (S.Y.Hu) Lo against H. pylori SCYA201401 at different concentrations.
Notes: MIC: minimum inhibitory concentration; TSG: Tinospora sagittata (Oliv.) Gagnep. var. craveniana (S.Y.Hu) Lo
Rong et al. BMC Complementary and Alternative Medicine  (2016) 16:331 Page 5 of 8
In our study, the MIC of TSG, 6.25 mg/mL, was
sufficient to completely eliminate H. pylori. Although
this MIC is lower than that in another study (16 μg/
mL) [35], it took longer than TSG to completely
eliminate the H. pylori strains we used. Our in vivo
experiments demonstrated the potential of TSG for
eradication of H. pylori, with efficacy equivalent to
that of triple therapy. The observation that palmatine
was less effective than TSG, implies that palmatine is
not the only component of TSG with bactericidal
effect against H. pylori. Like other herbs, TSG is a
complex compound, and some of it effective compo-
nents likely are yet unknown. Hence, further research
on TSG might prove useful in identifying components
that could have greater anti-H. pylori effect than has
palmatine. Nevertheless, this study confirms the in
vitro and in vivo anti-H. pylori effects of TSG and its
main component palmatine, and provide impetus for
future research with these agents.
The findings of our initial experiments with abattoir pigs
have important implications. We found a substantial
isolation rate (about 25 %) in abattoir pigs. Others [27]
have reported that in 60 farms in England, over 79 % of
porcine stomachs had either an oesophago-gastric ulcer
or visible pre-ulcerative changes. Although it was not
proven that H. pylori caused the abnormalities, it may
have, or the abnormalities may have been caused by a
related bacterium, such as Helicobacter heilmanni. The
ease of transmission of porcine H. pylori to mice in our
study indicates the possibility of zoonotic transmission of
H. pylori. Accordingly, colonization of domestic animals
has to be considered a possible cause of the high
prevalence of H. pylori infections in man.
The current medicinal treatment of H. pylori is
generally based on triple therapy regimen, inhibition of
gastric acid secretion by histamine H2-antagonists,
proton pump inhibitors, as well as on mucosal protect-
ive therapy provided by sucralfate and bismuth [28, 29].
Since antibiotic-resistant H. pylori strains triggered a
global pandemic and brought various harmful adverse
effects, the search for safe and effective non-antibiotic
agents is urgently required [30, 31]. In recent years, ac-
tive researches have rekindled interest in natural drugs
possessing these activities, which are widely appreciated
by the population especially in oriental countries [32].
Since improved medical therapy for human H. pylori
infection is clearly needed, the results of this study are
encouraging. Although their relevance to the management
Fig. 2 Time-kill curves of palmatine against H. pylori SCYA201401 at different concentrations. Note: MIC: minimum inhibitory concentration
Table 3 Results of rapid urease test and bacterial culture in the mouse model (n = 10)
Tests Blank
control
SCYA201401experimental group SS1 experimental group
Model Triple therapy TSG Palmatine Model Triple therapy TSG Palmatine
rapid urease test (n) 10 0 7 9 5 0 7 9 6
Bacterial culture (n) 10 0 7 8 5 0 7 8 6
Eradication ratio - 0/10 7/10 8/10 5/10* 0/10 7/10 8/10 6/10
*P < 0.05 vs. TSG group
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of human H. pylori infection is unknown, they do indicate
that non-antibiotic-based treatment options, such as
herbal medication, deserve consideration.
Conclusions
In experiments with an H. pylori strain isolated from
pigs and standard strain H. pylori SS1, the Chinese
herbal medicine TSG and is major active component,
palmatine, exhibited bactericidal effect in vitro and in a
murine model. The effect was of similar magnitude to
that of clarithromycin or triple therapy. In view of the
increasing antibiotic resistance of H. pylori and the side
effects associated with antibiotic-based therapy, the
possibility that herbal medications could provide effect-
ive and safe therapy of H. pylori infection deserves
investigation.
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